ERBB2 and cancer: Anthracyclines and the human ERBB2 monoclonal antibody (trastuzumab) are the two anti-cancer drugs associated with the highest cardiotoxicity risk, at times causing LV dysfunction and symptomatic HF, collectively termed cancer therapy-related cardiac dysfunction (CTRCD) [3].